Abstract
Autotaxin (ATX, autocrine motility factor, NPP2) has recently emerged as an attractive target for the development of anticancer chemotherapeutics. ATX contributes to the production of the bioactive lipid, lysophosphatidic acid (LPA), from lysophosphatidyl choline (LPC) in biological fluids including plasma, serum, and tumor cell effusates. LPA-stimulated cell proliferation, survival, motility and invasion have been demonstrated by numerous research groups. LPA receptors and ATX are upregulated in numerous cancer cell types and show expression patterns that correlate with tumor cell invasiveness. Despite considerable promise as an anti-cancer target, two complex challenges have slowed inhibitor discovery. The first of these challenges has been a lack of experimental details of the enzyme structure and its interactions with substrates or inhibitors. A second challenge has been a lack of structural diversity among initially reported inhibitors. Research reported in the last two years provides a foundation to begin addressing these challenges. Although an experimental structure of ATX is not among these recent developments, a crystal structure of the bacterial enzyme Xac. NPP is now available. This protein shares 35% identity with the central catalytic domain of ATX and provides an important starting point to begin understanding the structure of ATX. The structural diversity of known inhibitors has recently expanded to include not only phospholipid analogs, but also small molecules containing thiourea, diphenyldiazerenyl, anthracenedione and indole central cores. These two developments are essential tools for the discovery and optimization of ATX-targeted agents for evaluation as anti-cancer chemotherapeutic agents.
Keywords: Autotaxin Inhibition, Anti-Cancer Agents, chemotherapeutics, bioactive lipid, lysophosphatidic acid (LPA), proliferation, bacterial enzyme
Anti-Cancer Agents in Medicinal Chemistry
Title: Autotaxin Inhibition: Challenges and Progress Toward Novel Anti-Cancer Agents
Volume: 8 Issue: 8
Author(s): Abby L. Parrill and Daniel L. Baker
Affiliation:
Keywords: Autotaxin Inhibition, Anti-Cancer Agents, chemotherapeutics, bioactive lipid, lysophosphatidic acid (LPA), proliferation, bacterial enzyme
Abstract: Autotaxin (ATX, autocrine motility factor, NPP2) has recently emerged as an attractive target for the development of anticancer chemotherapeutics. ATX contributes to the production of the bioactive lipid, lysophosphatidic acid (LPA), from lysophosphatidyl choline (LPC) in biological fluids including plasma, serum, and tumor cell effusates. LPA-stimulated cell proliferation, survival, motility and invasion have been demonstrated by numerous research groups. LPA receptors and ATX are upregulated in numerous cancer cell types and show expression patterns that correlate with tumor cell invasiveness. Despite considerable promise as an anti-cancer target, two complex challenges have slowed inhibitor discovery. The first of these challenges has been a lack of experimental details of the enzyme structure and its interactions with substrates or inhibitors. A second challenge has been a lack of structural diversity among initially reported inhibitors. Research reported in the last two years provides a foundation to begin addressing these challenges. Although an experimental structure of ATX is not among these recent developments, a crystal structure of the bacterial enzyme Xac. NPP is now available. This protein shares 35% identity with the central catalytic domain of ATX and provides an important starting point to begin understanding the structure of ATX. The structural diversity of known inhibitors has recently expanded to include not only phospholipid analogs, but also small molecules containing thiourea, diphenyldiazerenyl, anthracenedione and indole central cores. These two developments are essential tools for the discovery and optimization of ATX-targeted agents for evaluation as anti-cancer chemotherapeutic agents.
Export Options
About this article
Cite this article as:
Parrill L. Abby and Baker L. Daniel, Autotaxin Inhibition: Challenges and Progress Toward Novel Anti-Cancer Agents, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (8) . https://dx.doi.org/10.2174/187152008786847765
DOI https://dx.doi.org/10.2174/187152008786847765 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Research Trends on Bismuth Compounds in Cancer Chemoand Radiotherapy
Current Medicinal Chemistry Morpholine Based Diazenyl Chalcones: Synthesis, Antimicrobial Screening and Cytotoxicity Study
Anti-Cancer Agents in Medicinal Chemistry Current Protein-based Anti-angiogenic Therapeutics
Mini-Reviews in Medicinal Chemistry Mechanisms of Angiogenesis: Perspectives from Antiangiogenic Tumor Therapies
Current Angiogenesis (Discontinued) Dual Inhibition of PI3-Kinase and mTOR in Renal Cell Carcinoma
Current Cancer Drug Targets Update on the Protective Renal Effects of Metformin in Diabetic Nephropathy
Current Medicinal Chemistry Similar and Shared Nongenomic Mechanisms of Action of Estrogen and Thyroid Hormone
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety Application of Phage Display Technology to Cancer Research
Current Pharmaceutical Biotechnology Development of Structure Activity Correlation Model on Azetidin-2-ones as Tubulin Polymerization Inhibitors
Letters in Drug Design & Discovery Antitumoral Activity of Interferon-γ Involved in Impaired Immune Function in Cancer Patients
Current Drug Metabolism Liposome Encapsulated All Trans Retinoic Acid (ATRA) has Enhanced Immunomodulatory and Inflammation Reducing Activities in Mice Model
Anti-Cancer Agents in Medicinal Chemistry Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
Current Medicinal Chemistry Pharmacological Histone Deacetylation Distinguishes Transcriptional Regulators
Current Topics in Medicinal Chemistry Graphical Abstracts:
Current Nanoscience Current Drug Targets for Modulating Alzheimer's Amyloid Precursor Protein: Role of Specific Micro-RNA Species
Current Medicinal Chemistry Angiogenesis as a Therapeutic Target in Arthritis: Lessons from Oncology
Current Pharmaceutical Design Opioids and Opioid Maintenance Therapies: Their Impact on Monocyte-Mediated HIV Neuropathogenesis
Current HIV Research Noninvasive Diagnosis of Chemotherapy Related Cardiotoxicity
Current Cardiology Reviews Identification of Molecular Targets Associated with Ethanol Toxicity and Implications in Drug Development
Current Pharmaceutical Design